Company profile
Theolytics | Biotech | England
Everyone should have access to innovative therapies that represent the promise of lasting cures. Theolytics is a biotech company working to transform patients lives, through world leading science, with a great team.
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
AD01 | Transaction MzUyNzUzNTczN2FkaXF6a2N4
Published 22 Jun 2026 09:47
AP01 | Transaction MzUyNTU4NzQwOGFkaXF6a2N4
Published 07 Jun 2026 08:04
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQzOTMyNjc3NWFkaXF6a2N4
Published 14 Oct 2024 11:06
AP01 | Transaction MzQzNzY4OTA5MmFkaXF6a2N4
Published 30 Sep 2024 09:03
TM01 | Transaction MzQzNzY4MzI5M2FkaXF6a2N4
Published 30 Sep 2024 08:40
AP01 | Transaction MzQzNzY4MzI4OGFkaXF6a2N4
Published 30 Sep 2024 08:40
TM01 | Transaction MzQzNzY4MjQ2OGFkaXF6a2N4
Published 30 Sep 2024 08:36
SH01 | Transaction MzQzNTk4NTk2MWFkaXF6a2N4
Published 16 Sep 2024 10:08
CAP-SS | Transaction MzQzNTU5ODM2NmFkaXF6a2N4 | Paper/PDF filed
Published 14 Sep 2024 06:57
SH19 | Transaction MzQzNTU5ODYzNGFkaXF6a2N4 | Paper/PDF filed
Published 14 Sep 2024 06:49
RESOLUTIONS | Transaction WURCSzVVRTJhZGlxemtjeA | Paper/PDF filed
Published 14 Sep 2024 06:48
SH20 | Transaction MzQzNTU5ODUyMGFkaXF6a2N4 | Paper/PDF filed
Published 14 Sep 2024 06:44
SH01 | Transaction MzQzNDQ2MTQxN2FkaXF6a2N4
Published 04 Sep 2024 08:49
SH01 | Transaction MzQzNDQ2MTA2OGFkaXF6a2N4
Published 04 Sep 2024 08:44
SH01 | Transaction MzQzMjkyODgzOGFkaXF6a2N4
Published 21 Aug 2024 11:10
Company registered at Companies House
1 Aug 2024 to 31 Jul 2026
Annually 7,495 women in the UK are diagnosed with ovarian cancer (OC). \>75% of cases are diagnosed at an advanced stage (grade-III/IV) with poor long-term outcomes (<25% 5-year survival). Standard-of-care first-line treatments combine cytoreductive surgery, platinum-based chemotherapies, and paclitaxel. Although initially effective, most patients relapse...
1 May 2022 to 30 Apr 2024
Multiple myeloma (MM) is an incurable blood cancer affecting ~5,800 UK citizens each year. Prognosis is poor with a <29% 10-year survival rate. MM treatments are given in cycles of triplet chemo-, immuno-, and corticosteroid- therapeutic combinations. Periods of remission between cycles become increasingly shorter (from 2+ years to <6-months) as the disea...
1 Nov 2020 to 30 Apr 2022
Ovarian cancer (OC) is the 6th most common cause of cancer death. Annually \>7,443 women are diagnosed (\>240,000 globally). Mortality rates are \>65%, with most patients succumbing within 5-years. OC is frequently diagnosed at a late stage making it difficult to treat. Whilst initial response to chemotherapy is high, most patients (\>80%) quickly acquire...
